Sign in
Active, not recruitingPhase 1/2

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Key facts

Who runs it
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Where
Torrance, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 1/2
People taking part
14 people, planned
Started
5 Jun 2017
Expected to end
Feb 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Adalimumab Injection [Humira]
  • Saline Solution for Injection
Record updated
2 February 2026

Who can take part

Age
5 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Male or female ≥5 years of age
  • Diagnosis of MPS I, II or VI
  • Treatment with ERT for ≥1 year or no treatment with ERT for ≥1 year
  • Weight ≥15 kg
  • Significant bodily pain reported by the CHQ-PF50 or SF-36 (> 1 SD more severe [below] than the general population mean)
  • ≥ 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided

Who cannot take part

  • History of HCT less than 2 years prior to enrollment
  • Immune suppression therapy less than 1 year prior to enrollment
  • Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment
  • Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or
  • Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study
  • Active graft versus host disease
  • Current diagnosis or history of lymphoma or other malignancy
  • Current active infection
  • History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections)
  • Congestive heart failure defined by an ejection fracture <50% measured by ECHO
  • Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome)
  • Hepatitis B infection (active or chronic carrier)
  • Known or suspected allergy to adalimumab or related products
  • Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB
  • Hematologic abnormalities (e.g., pancytopenia, aplastic anemia)
  • Latex sensitivity
  • Pregnancy or breastfeeding

Where in United States

  • The Lundquist Institute at Harbor UCLA Medical CenterTorrance, United States

About the trial

What the trial wants to find out

Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.

The 3 groups in the trial

  • AdalimumabTreatment being tested

    20 mg subQ every other week (weight 15to \<30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.

    Treatment: Adalimumab Injection [Humira]

  • PlaceboPlacebo, for comparison

    Saline placebo comparator

    Treatment: Saline Solution for Injection

  • Open-label adalimumabTreatment being tested

    Open-label extension of adalimumab dose

    Treatment: Adalimumab Injection [Humira]

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI
Record updated
2 February 2026